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Abstract
Neurodevelopmental disorders such as attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) 
are highly heritable and influenced by many single nucleotide polymorphisms (SNPs). SNPs can be used to calculate indi-
vidual polygenic risk scores (PRS) for a disorder. We aim to explore the association between the PRS for ADHD, ASD and 
for Schizophrenia (SCZ), and ADHD and ASD diagnoses in a clinical child and adolescent population. Based on the most 
recent genome wide association studies of ADHD, ASD and SCZ, PRS of each disorder were calculated for individuals of 
a clinical child and adolescent target sample (N = 688) and for adult controls (N = 943). We tested with logistic regression 
analyses for an association with (1) a single diagnosis of ADHD (N = 280), (2) a single diagnosis of ASD (N = 295), and 
(3) combining the two diagnoses, thus subjects with either ASD, ADHD or both (N = 688). Our results showed a significant 
association of the ADHD PRS with ADHD status (OR 1.6, P = 1.39 × 10−07) and with the combined ADHD/ASD status 
(OR 1.36, P = 1.211 × 10−05), but not with ASD status (OR 1.14, P = 1). No associations for the ASD and SCZ PRS were 
observed. In sum, the PRS of ADHD is significantly associated with the combined ADHD/ASD status. Yet, this association 
is primarily driven by ADHD status, suggesting disorder specific genetic effects of the ADHD PRS.
Keywords Polygenic risk score · Psychiatric disorders · Autism spectrum disorder (ASD) · ADHD · Child behavioral 
checklist (CBCL) · Schizophrenia
Introduction
Psychiatric disorders are heritable complex traits with var-
ying heritability estimates. At the top end of the heritabil-
ity range, reported heritabilities vary from 74% for ASD 
(Tick et al. 2016) to 80% for ADHD (Brikell et al. 2015), 
and 81% for SCZ (Sullivan et al. 2003). These traits likely 
have a similar genetic architecture with a role for common 
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and rare variants, including de novo mutations and copy 
number variants (CNV) playing an important role (Gratten 
et al. 2014). Common genetic variation can be captured 
in a polygenic signal that contains a multitude of single 
nucleotide polymorphisms (SNPs) from many genes (Grat-
ten et al. 2014; Sullivan et al. 2012). Genome-wide asso-
ciation studies (GWAS) are a highly successful method 
to identify the common variants that influence these dis-
orders (Visscher et al. 2017). GWAS reveal increasingly 
more significantly associated loci. These represent the 
most associated part of the genetic signal. The most recent 
GWAS for ADHD, ASD, and SCZ identified 12, 5, and 
145 independent associated loci, respectively (Demontis 
and Walters 2017; Grove et al. 2017; Pardiñas et al. 2018).
However, given the polygenicity of disorders like 
ADHD and ASD, also non-significantly associated SNPs 
are likely to contribute to the disorder (Wray et al. 2014). 
Hence, it is also of interest to investigate the non-genome-
wide significant component of the genetic signal.
One method to include the non-genome-wide signifi-
cant component of the common genetic variation is the 
polygenic risk scores (PRS) approach. PRS are the sum of 
risk alleles weighted by their estimated effect size as deter-
mined in an independent GWAS sample, and can serve 
as such as an estimation of an individual’s polygenic risk 
(Torkamani et al. 2018; Weiner et al. 2017; Wray et al. 
2014). PRS estimated from an independent sample can 
be used for prediction between groups (e.g., cases and 
controls), or for stratifying groups of people according 
to high or low genetic risk as defined by their PRS. For 
example, in a sample of children from the general popula-
tion, the SCZ PRS has shown positive associations with 
behavioral and emotional problems in children as young as 
3 years old (Jansen et al. 2017). Similarly, the ADHD PRS 
has been associated with attention problems in children 
from the general population (Groen-Blokhuis et al. 2014), 
and with attentional and hyperactive-impulsive traits in 
another general population sample (age ~ 7 year, 7 months) 
(Martin et al. 2014).
As previous research indicates, the common genetic 
burden of different psychiatric disorders partially overlaps 
(Mitchell 2011). To add, both ADHD and ASD, as well as 
SCZ, are regarded neurodevelopmental disorders (NDD) 
(Mullin et al. 2013; Rapoport et al. 2012) and genetic 
studies have shown positive genetic correlations of 0.36 
for ASD/ADHD (Grove et al. 2017), 0.211 for ASD/SCZ 
(Grove et al. 2017), and 0.122 for ADHD/SCZ (Demontis 
and Walters 2017).
In addition, it was shown that the prevalence of SCZ 
is significantly higher in an ASD sample compared to 
controls (OR 3.55, 95% CI 2.08–6.05, P < 0.001), and the 
prevalence of ASD in an SCZ samples ranges between 3.4 
and 52% compared to 1% in the general population (Zheng 
et al. 2018). To add, ASD and SCZ share clinical features 
among which social cognition (Cheung et al. 2010; DSM 
5 2013), while ASD and ADHD share inattention (Craig 
et al. 2015; DSM 5 2013).
The current study adds to this literature by investigat-
ing associations of the ADHD, ASD, and SCZ PRS in a 
sample of children and adolescents referred to an outpa-
tient university clinic. The children in this sample were 
assessed with standardized procedures generating clinical 
(DSM-IV) diagnoses as well as continuous rating scale 
scores on behavioral/emotional problems. We aim to 
investigate whether PRS for ADHD (Demontis and Wal-
ters 2017), ASD (Grove et al. 2017) and SCZ (Pardiñas 
et al. 2018) can distinguish ADHD and ASD cases from 
controls in this sample. Findings from genetic studies sug-
gest a partly shared genetic diathesis underlying neurode-
velopmental disorders (including SCZ, ASD and ADHD) 
(Bulik-Sullivan et al. 2015). We therefore hypothesized 
that the ADHD, ASD and SCZ PRS would be associated 
with the ADHD/ASD (either ASD, ADHD or both) diag-
nostic status. In addition, we expected both the ADHD and 
ASD PRS to be associated with ADHD and ASD respec-
tively. In addition, we expected the SCZ PRS to be associ-
ated with ASD status given the genetic overlap previously 
reported (Autism Spectrum Disorders Working Group of 
The Psychiatric Genomics Consortium 2017), although 
conflicting results with low (Cross-Disorder Group of the 
Psychiatric Genomics Consortium et al. 2013) or no (Vor-
stman et al. 2013) genetic association between ASD and 
SCZ have been reported as well. As a sensitivity analysis, 
we aim to perform a follow up correlation analysis and 
subsequently a linear regression analysis with the Child 
Behavioral Checklist (CBCL) subscales to validate the 
robustness of our findings and gain additional information 
on the link between associated genetic signals and specific 
behavioral or emotional problems, given a particular clini-
cal diagnosis.
Methods
Sample
Psychiatric outpatient sample: “Inside‑Out”
A new psychiatric outpatient sample called “Inside-Out” is 
analyzed. Data were collected from January 2001 until Janu-
ary 2012 at the department of Child and Adolescent Psychia-
try at the Sophia Children’s Hospital at Erasmus Medical 
Center in Rotterdam, resulting in a psychiatric outpatient 
sample. Before the first visit, parents and children received 
the CBCL from the Achenbach System of Empirically Based 
Assessment (ASEBA) (Achenbach and Rescorla 2001). In 
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addition, DNA was extracted from saliva and genotyping 
was performed on the Illumina PsychChip array (see data). 
The procedure was approved by the ethical committee of 
the Erasmus Medical Center. The total Inside-Out sample 
comprises 1941 children diagnosed with one or more DSM-
IV disorders (ASD, ADHD, Tic disorder, Obsessive Com-
pulsive Disorder (OCD), Depression, Anxiety, Anorexia 
Nervosa (AN), eating disorder NOS, RETT syndrome and 
subcategories of mentioned disorders) and children with a 
delayed diagnostic status or children who did not receive 
a DSM diagnosis (27.9%). The diagnostic procedure con-
sisted of an interview with parents, a semi-structured inter-
view with the child based on the Semi-structured Clinical 
Interview for Children and Adolescents (McConaughy and 
Achenbach 2001), the Diagnostic Interview Schedule for 
Children IV-P (Shaffer et al. 2000) and the Autism Diag-
nostic Observation Schedule-Generic (Lord et al. 1989) in 
case of a suspected autism spectrum disorder. Diagnostic 
classification was done by a clinician according to the Diag-
nostic and Statistical Manual of Mental Disorders, fourth 
edition (DSM-IV). The above-mentioned procedure was part 
of standard clinical practice For the current study, genetic 
and clinical information was used of the children who 
received an ADHD diagnosis, no ASD co-diagnosis allowed 
(N = 280, age range: 3.3–18.5 years, mean: 9.06, SD: 2.66) 
or an ASD diagnosis, no ADHD co-diagnosis allowed 
(RETT excluded) (N = 295, age range: 2.5–18.3 years, mean: 
9.02, SD: 3.55). In addition we used a sample of combined 
ADHD and ASD diagnoses where comorbidity of ADHD 
and ASD was allowed, adding another 113 children to this 
combined sample (N = 688, age range 2.5–18.5, Mean: 8.96, 
SD: 3.07). The target sample was diagnosed with the DSM-
IV and includes many cases with Asperger and pervasive 
developmental disorder-not otherwise specified (PDD-NOS) 
diagnoses (82% of total ASD sample). ADHD and ASD 
co-diagnosed children (N = 113) were not included in the 
ADHD and ASD sample. For sample specifics see Tables 1 
and 2. 
Population‑based control sample
As a control sample, we used a Dutch population sample 
(NESCOG, N = 943, age range: 17.0–79.0) previously 
described by Polderman et al. (2013). NESCOG comprises 
a general population and a family-based sample of which 
closely related individuals were excluded. Data were col-
lected on cognitive tasks, behavioral conditions (such as 
ADHD and ASD symptoms), life events, personality and 
environmental factors, as well as genetic information. More-
over, to correct for undiagnosed ADHD status, participants 
scoring 3 SD above the mean on the Conners’ Adult ADHD 
Rating Scale (CAARS) (Conners et al. z.d.), or the Attention 
Table 1  Sample overview
ASD autism spectrum disorder, ADHD attention deficit/hyperactivity disorder, SCZ schizophrenia, CBCL child behavioral checklist, AQ autism 
quotient, CAARS Conners’ Adult ADHD Rating Scale
Sample N Reference
Discovery samples used for computation of PRS
 Discovery sample ADHD Cases: 20.183
Controls: 35.191
Demontis et al. (2019)
 Discovery sample ASD Cases: 18.381
Controls: 27.969
Grove et al. (2019)
 Discovery sample SCZ Cases: 40.675
Controls: 64.643
Pardinas et al. (2018)
Sample N Additional information
Target samples used for case control studies: Inside-out (logistic regression)
 ADHD/ASD sample 688 ADHD/ASD comorbidity allowed, therefore including 113 
extra children
 ADHD sample 280 Subset of ADHD/ASD sample based on diagnostic status. 
ADHD/ASD comorbidity NOT allowed
 ASD sample 295 Subset of ADHD/ASD sample based on diagnostic status. 
ADHD/ASD comorbidity NOT allowed
 Control sample 943 NESCOG general population sample corrected for high 
scores on AQ and CAARS
Target sample used for sensitivity analysis: inside-out (correlations PRS-syndrome and CBCL scales)
 ADHD/ASD sample 530 Sub set of ADHD/ASD sample based on the presence 
of the CBCL for age 6-18 and hence, diagnostic age. 
ADHD/ASD comorbidity allowed
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Problems scale of the Young Adult Self Report (YASR) 
(Achenbach 1997) were excluded. Participants scoring three 
SD above mean on the Autism Quotient (AQ) (Baron-Cohen 
et al. 2001) were also excluded, resulting in a final control 
sample of 943 participants (age range 17–79, 38% male), 
see Tables 1 and 2.
Data
Genotyping of the cases and controls was performed on the 
same Illumina PsychChip array. The PsychChip SNP array 
contains HumanCore, Human Exome and custom content to 
accurately capture genetic variants previously linked with 
psychiatric disorders (https ://www.illum ina.com/produ cts/
by-type/micro array -kits/infin ium-psych array .html). Genetic 
variants in the clinical sample were filtered based on minor 
allele frequency (MAF < 1%), Hardy–Weinberg disequilib-
rium (P < 1 × 10−6) and SNP call rate (< 95%). Individuals 
were subsequently filtered based on relatedness (pairwise 
Identity-By-Descent (IBD) > 0.185), genotype and phe-
notypic sex mismatch, outlying heterozygosity and non-
European ancestry (4 SD outside the range of the first two 
genetic principal components of the HapMap3 European 
founder population (CEU)) resulting in a clinical sample of 
812 patients of which 688 are diagnosed with ADHD, ASD 
or both. The remaining part of the children in this sample 
(N = 124) are diagnosed with either Rett syndrome, Ano-
rexia Nervosa or other eating disorders, Tourette Disorder, 
or other disorders. Another subset of the sample is currently 
being genotyped and includes children diagnosed with Anxi-
ety Disorder, Affective Disorder or other disorders. In the 
control sample, SNP filtering was based on MAF (< 1%) 
Hardy–Weinberg disequilibrium (P < 0.00001) and SNP 
call rate (< 95%). Individual QC was based on missingness 
(> 5%), ancestry (within the range of 1000G CEU popula-
tion on first PCs), relatedness (pairwise IBD > 0.185), gender 
mismatch, outlying heterozygosity and missing phenotypes.
Sex differences in the samples
The case and control samples differed in sex distribution 
(cases are 75% and the controls 25% males). Therefore, we 
compared allele frequencies between males and females in 
an independent sample, GoNL (see www.nlgen ome.nl for 
more information), by means of correlation. The Pearson 
correlation coefficient between the male and female allele 
frequencies is 0.99, removing concerns of different allele 
frequencies in the two samples due to sex differences.
Polygenic risk scoring
The PRS is constructed as the sum of risk alleles weighted 
by their effect size. Per disorder several PRS were calculated 
with different P value inclusion thresholds (P-values: < 0.01, 
< 0.05, < 0.1, < 0.2, < 0.3, < 0.4, < 0.5, < 1). Starting from 
a low P-value threshold moving up to P-value 1, an opti-
mal P-value threshold with the highest explained variance 
was identified, including the most truly associated positives. 
After this threshold more false positives will be included 
dampening the true signal. (Wray et al. 2014). Prior to our 
calculation of the PRS, the SNPs were pruned (LD  R2 < 0.1, 
250 kb pair window) to remove variants in LD. Polygenic 
scoring was performed with the software package PRSice 
(Euesden et al. 2015). The PRS for ASD, ADHD and SCZ 
were constructed using the most recent summary statistics 
from GWAS with the largest publicly available sample size, 
ADHD (Demontis and Walters 2017) (20,183 cases and 
35,191 controls), ASD (Grove et al. 2017) (18,382 cases 
and 27,969 controls), and SCZ (Pardiñas et al. 2018) (40,675 
cases and 64,643 controls). Of note, the Inside-Out and 
the control sample are independent samples, not included 
in these GWAS. After polygenic scoring the results were 
standardized to mean 0 and SD 1 for interpretational pur-
poses. For the number of SNPs included in the scores see 
Supplementary Table S1.
Table 2  Sample description
ADHD/ASD = ADHD (280) + ASD (295) plus children codiagnosed with ADHD and ASD (113)
a Sample size differs from the sample size for the logistic regression due to CBCL 6–18 (age range) avail-
ability
Sample logistic regression Sample correlation analysis
ADHD/ASD ADHD ASD Control ADHD/ASDa
N 688 280 295 943 530
Age range 
(mean, SD) in 
years
2.5–18.5 (8.96, 3.07) 3.3–18.5 
(9.06, 
2.66)
2.5–18.3 
(9.02, 
3.55)
17.0–79.0 
(44.47, 
13.94)
6.05–18.52 (9.7, 2.60)
Gender  % male 76 75 73 38 75
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Behavioral measurements
Child emotional and behavioral problems were assessed 
using the Dutch version of the Child Behavior Check-
list/6–18 (CBCL) (Achenbach and Rescorla 2001) filled out 
by the parent before the first visit to the hospital. The CBCL 
contains 113 problem items that can be scored on eight syn-
drome scales (Anxious/Depressed  Nitem = 13, Withdrawn/
Depressed  Nitem = 8, Somatic Complaints  Nitem = 11, Social 
Problems  Nitem = 11, Thought Problems  Nitem = 15, Attention 
Problems  Nitem = 10, Rule Breaking Behavior  Nitem = 17 and 
Aggressive Behavior  Nitem = 18). Parents score each problem 
on a three-point scale (0: not true, 1: somewhat or sometimes 
true, 2: very or often true). This follow up analysis included 
children with a CBCL 6–18 report, completed by the parent 
less than a year before receiving the diagnosis. If a CBCL 
from within a year before diagnosis was not present the per-
son was excluded from this part of the analysis. In all analy-
ses, sum scores on the CBCL syndrome scales were used.
Statistical analysis
Case control analysis on the association between PRS 
and disease status
We performed logistic regression analyses to investigate if 
the ADHD, ASD or SCZ PRS can distinguish between cases 
and controls in a sample (1) with a diagnosis of ADHD, 
ASD not permitted as co-diagnosis (ADHD, N = 280), (2) 
with a diagnosis of ASD, ADHD not permitted as co-diag-
nosis (ASD, N = 295), and (3) combining the first two sam-
ples, thus subjects with either ASD, ADHD or both (ADHD/
ASD, N = 688). For each PRS, eight different SNP inclu-
sion thresholds were tested. All P-values were corrected 
for multiple testing by means of Bonferroni correction (72 
tests: three samples (ADHD, ASD, ADHD/ASD), three PRS 
(ADHD, ASD, SCZ), eight PRS thresholds (0.01, 0.05, 0.1, 
0.2, 0.3, 0.4, 0.5, 1) per disorder). To account for popula-
tion stratification we included eight principal components 
(PCs). The PCs were calculated based on the pruned data 
with Eigensoft (Price et al. 2006) (version 3.0) software. 
Additionally, sex was added as a covariate. Age was not 
added as a covariate as all cases are children and all controls 
are adults.
Sensitivity analysis: correlation and association 
between CBCL syndrome scales and PRS
We aim to provide additional evidence for the significant 
association of the PRS and the disorders as measured by 
the CBCL score severity. Given statistical power, we tested 
the association with symptom severity only in the combined 
ADHD/ASD sample by calculating the correlation between 
the significantly associated PRS (i.e., ADHD) and the syn-
drome scales of the CBCL. Age was added as a covariate 
in addition to the previously used eight PCs and sex. All 
analyses were performed in IBM SPSS statistics 21.
Results
Case control analysis on the association 
between PRS and disorder status
The ADHD PRS showed significant associations before mul-
tiple testing correction with disorder status in all three sam-
ples (Table 3). As shown in Fig. 1, all ADHD PRS P-value 
thresholds remained significant after Bonferroni multiple 
testing correction in both the combined ADHD/ASD and 
ADHD sample, but not the ASD sample. The most stringent 
P-value threshold of 0.01 generated a positive association 
in the ADHD/ASD sample OR 1.28 (P = 1.3 × 10−3), and 
ADHD sample OR 1.4 (P = 3.6 × 10−4). The most optimal 
P-value threshold as defined by explained variance, OR and 
P-value was 0.3 for the ADHD/ASD sample  (R2 = 0.02, 
OR 1.36, P = 1.21 × 10−05), and 0.4 for the ADHD sample 
 (R2 = 0.045, OR 1.62, P = 5.75 × 10−08).
The most lenient P-value threshold of P < 1 had a sig-
nificant association in the ADHD/ASD sample, OR 1.35 
(P = 1.9 × 10−5), and also in the ADHD sample OR 1.62 
(P = 4.73 × 10−8). In the ASD sample none of the results 
remained significant after Bonferroni correction.
The ASD and SCZ PRS were not significantly associated 
with the ADHD, ASD, or combined ADHD/ASD status. 
The SCZ PRS including all SNPs (P-value threshold P < 1) 
showed a trend towards association in the ADHD/ASD sam-
ple (OR 1.13, P = 5.72 × 10−2) (Supplementary Tables S2 
and S3 and Figs. S1 and S2).
Sensitivity analysis: association between CBCL 
syndrome scales and the ADHD PRS
Based on the correlational structure in the ADHD/ASD 
sample (Supplemental Material Table 4) between the CBCL 
syndrome scale scores and the ADHD PRS P-value thresh-
olds, we concluded the correlation was too low (all correla-
tions ≤ 0.1) to warrant the linear regression analysis. Mean 
scores and standard deviations for the CBCL syndrome scale 
scores for the ADHD/ASD sample are provided in Supple-
mentary Table 5.
 Behavior Genetics
1 3
Discussion
This study investigated the associations of PRS for ADHD, 
ASD and SCZ, with ADHD and ASD status in a clinical 
child and adolescent population. As hypothesized, we found 
a significant association between the ADHD PRS and the 
combined ADHD/ASD status, and the separate ADHD sta-
tus. The PRS SNP-inclusion thresholding resulted in a rise 
of explained variance with increasing P-value thresholds, 
showing that in addition to the GWAS significant hits, the 
non-significant SNPs in the ADHD GWAS also contribute 
to the associations with diagnostic status. Given the comor-
bidity between ADHD and ASD, and previously reported 
genetic correlations, we expected that the ADHD PRS would 
also be associated with ASD status, however, this associa-
tion was not observed in our data. In contrast, the current 
results suggest a disorder specific effect of ADHD associated 
SNPs instead of a shared common genetic mechanism with 
ASD. The ADHD PRS is based on the most recent GWAS 
results, and explained variance up to 4.5% in our sample, 
which is in line with the results from the initial GWAS 
(Demontis and Walters 2017) who reported an explained 
variance of 5.5%, making it a promising PRS for further use 
in research on ADHD.
Contrary to our expectation, the ASD and SCZ PRS were 
not associated with any of the diagnostic groups. The null 
results for the ASD PRS are unexpected as the initial GWAS 
(Grove et al. 2017) reported an explained variance of 2.45% 
in an independent sample, and their summary statistics were 
used for the analysis. Given that the discovery sample size of 
ASD was only slightly smaller than the ADHD sample, and 
the SCZ sample was even larger, we do not expect that sam-
ple size alone explains these findings. Moreover, apart from 
sample size, power analyses usually take several parameters 
into account, including the heritability and population preva-
lence of traits, the amount of SNPs included in the GWAS, 
Table 3  Results of the logistic 
regression analyses for the 
ADHD PRS
All models have eight PCs and sex as covariate (baseline model). Bonferroni P-value corrected for 72 tests. 
Sig. P-values are shown in bold. Results of the logistic regression analyses for the ASD and SCZ PRS are 
presented in the Supplementary Tables 3 and 4
ADHD PRS 
threshold
B Wald p uncorrected Bonferroni corr. Wald p OR Nagel-
kerke  R2 
PRS
ADHD/ASD sample (N = 688)
 0.01 0.243 1.80 × 10−05 1.30 × 10−03 1.275 0.013
 0.05 0.274 2.00 × 10−06 1.44 × 10−04 1.316 0.016
 0.1 0.278 2.00 × 10−06 1.44 × 10−04 1.321 0.017
 0.2 0.287 7.91 × 10−07 5.70 × 10−05 1.333 0.018
 0.3 0.304 1.68 × 10−07 1.21 × 10−05 1.355 0.020
 0.4 0.297 2.96 × 10−07 2.13 × 10−05 1.346 0.019
 0.5 0.297 2.88 × 10−07 2.07 × 10−05 1.346 0.019
 1 0.297 2.71 × 10−07 1.95 × 10−05 1.346 0.019
ADHD sample (N = 280)
 0.01 0.337 5.00 × 10−06 3.60 × 10−04 1.401 0.024
 0.05 0.356 2.00 × 10−06 1.44 × 10−04 1.428 0.026
 0.1 0.401 2.52 × 10−07 1.82 × 10−05 1.493 0.031
 0.2 0.454 9.68 × 10−09 6.97 × 10−07 1.574 0.039
 0.3 0.472 1.93 × 10−09 1.39 × 10−07 1.603 0.043
 0.4 0.482 7.98 × 10−10 5.75 × 10−08 1.620 0.045
 0.5 0.479 9.87 × 10−10 7.11 × 10−08 1.614 0.044
 1 0.485 6.57 × 10−10 4.73 × 10−08 1.625 0.045
ASD sample (N = 295)
 0.01 0.176 1.45 × 10−02 1 1.192 0.007
 0.05 0.201 7.33 × 10−03 5.28 × 10−01 1.222 0.008
 0.1 0.169 2.35 × 10−02 1 1.184 0.006
 0.2 0.132 7.82 × 10−02 1 1.141 0.003
 0.3 0.135 6.83 × 10−02 1 1.144 0.004
 0.4 0.119 1.05 × 10−01 1 1.127 0.003
 0.5 0.129 7.83 × 10−02 1 1.138 0.003
 1 0.130 7.68 × 10−02 1 1.139 0.004
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the effective number of chromosome segments, and the pro-
portion of cases in discovery and target sample (Lee et al. 
2017). In our study, the discovery and target samples were 
for most of the parameters similar across disorders, except 
for prevalence rates (ASD and SCZ have a population preva-
lence of 1%, and ADHD has a population prevalence of 5%).
Regarding the null result for the ASD PRS one explana-
tion might be a difference in the diagnostic sample compo-
sition of the ASD GWAS discovery sample compared to 
the target ASD sample. The target sample was diagnosed 
with the DSM-IV and includes many cases with Asper-
ger, and PDD-NOS diagnoses (82% of total ASD sample), 
which might differ from the discovery sample. Moreover, 
about one-third of the discovery sample were trio data (i.e. 
case pseudo control design), of which it has been suggested 
that the un-transmitted chromosomes contain increased poly-
genic burden, and as such the genetic signal based on these 
data might be decreased (Peyrot et al. 2016). Additionally, 
the genetic architecture of ADHD might differ from ASD, 
e.g., rare genetic variants might comprise a more impor-
tant part of the genetic contribution to ASD (Geschwind 
and State 2015) compared to ADHD. With growing sam-
ple sizes, genetic discoveries will increase and become 
more reliable, potentially allowing the identification of rare 
variants.
The choice of including the SCZ PRS was based partly 
on the higher prevalence rate of SCZ in ASD individuals 
compared to the general population, a recent systematic 
review reports a significantly higher SCZ prevalence in 
ASD individuals compared to the general population (OR 
3.55, 95% confidence interval (CI) 2.08–6.05, P < 0.001) 
(Zheng et al. 2018). If the actual SCZ prevalence rate in 
an ASD population resides at the lower end of the of the 
95% CI the enrichment of common SCZ SNPs might not be 
detectable in our relatively small sample. Additionally, the 
genetic correlation of 0.211 between ASD and SCZ (Grove 
et al. 2017) and 0.122 between SCZ and ADHD (Demontis 
and Walters 2017) might be too small to detect the genetic 
overlap between the two disorders in our data. Finally, it 
is possible that ASD has a different genetic underpinning 
with more rare variants than SCZ although some overlap 
has been reported in rare genetic variation between ASD and 
SCZ (Sanders et al. 2015). Recent whole-genome sequence 
research on height fully recovered the heritability of this 
trait, meaning that next to the previously established com-
mon variants, all rare variants have been discovered (Wain-
schtein et al. 2019). Whole-genome sequence research into 
ASD, SCZ and ADHD might shed light on this issue reveal-
ing the genetic architecture of these traits.
The sensitivity analyses exploring the associations 
between scores on the syndrome scales of the CBCL and 
the ADHD PRS showed low correlations between these two 
measures, as such we decided not to pursue the follow-up 
analysis further. A reason for the low correlations can be 
the amount variance explained by the ADHD PRS. The 
explained variance of 4.5% might not be enough to give 
Fig. 1  Variance explained 
(Nagelkerke  R2) by the ADHD 
PRS. All SNP inclusion P-value 
thresholds are shown from low 
to high (0.01, 0.05, 0.1, 0.2, 0.3, 
0.4, 0.5, 1). P-values are shown 
on top of each bar and are Bon-
ferroni corrected
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meaningful results in follow-up analysis using the CBCL in 
a smaller sample like “Inside out”. In addition, a diagnosis 
is not based solely on the CBCL results but includes careful 
evaluation by an experienced psychologist/psychiatrist based 
on a patient interview, a parent interview and if possible an 
evaluation by a third party like a school teacher of the child.
Strengths and limitations
A strength of our study is the adult control sample as, in con-
trast to a child sample, the chance that adult individuals will 
receive a future ADHD or ASD diagnosis is limited com-
pared to young individuals i.e., these disorders are usually 
diagnosed during childhood (Nylander et al. 2013), while 
DNA sequences are fixed during life.
One concern might be the difference in sex distribution 
between the samples, with the clinical sample consisting 
of 75% males and the control sample having an opposite 
skew in sex distribution, as this could potentially affect the 
observed associations between the PRS and diagnoses. How-
ever, we compared the allele frequencies between males and 
females in an independent sample (GoNL (Genome of the 
Netherlands Consortium 2014)) and found no differences. 
Yet, due to the skewed sex distribution we could not exam-
ine sex-PRS interactions, or sex specific associations, which 
would both be interesting to investigate given the higher 
prevalence of males in both ADHD and ASD.
We also need to take into account that the ADHD/ASD 
group comprises the ADHD and ASD groups and that this 
is no official diagnostic disorder classification. The results 
should be replicated in a comparable independent sample 
first before firm conclusions can be drawn.
Overall, despite the fact that symptoms overlap between 
the neurodevelopmental disorders, our study does not 
directly imply that the umbrella of NDD is present at the 
common genetic level as captured in the PRS. As the ASD 
and SCZ PRS do not distinguish cases from controls in any 
of our diagnostic samples it is possible that ADHD, ASD 
and SCZ have a different common genetic signature. Moreo-
ver, the results should be replicated in one or more independ-
ent samples.
A final remark can be made on the cross sectional nature 
of the sample. Unlike longitudinal studies, measures are 
available for one point in time for most of the subjects. This 
presents the possibility that children might receive additional 
diagnoses later on in life resulting in a change in diagnostic 
status from ADHD or ASD to the ADHD/ASD codiagnosed 
group, or to other comorbidities.
Conclusions
In conclusion, the PRS of ADHD is significantly associated 
with the combined ADHD/ASD and ADHD status. Yet, this 
association is primarily driven by ADHD status, suggesting 
disorder specific genetic effects of the ADHD PRS. Never-
theless, it is of interest to explore the genetic predictive value 
of other psychiatric disorders besides neurodevelopmental 
disorders. Improving genetic prediction in neurodevelop-
mental disorders by using a multi-trait predictor instead of 
single-trait predictors is also an interesting option (Maier 
et al. 2018). Lastly, it is of interest to delve deeper into the 
association between the ADHD PRS and the specific emo-
tional and behavioral problems in larger samples as those 
data may provide additional information on specific prob-
lems or the severity of problems within a diagnostic status.
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